Imaging and Pathology Correlations for Different Risk Stratification Models for Intermediate-risk Prostate Cancer.
We evaluated whether sub-stratifying intermediate-risk (IR) prostate cancer using the Memorial Sloan Kettering Cancer (MSKCC) or Prostate Cancer Risk Stratification (ProCaRS) model predicts for adverse imaging or pathologic features.



56 consecutive IR patients who underwent multi-parametric MRI (mpMRI) and radical prostatectomy (RP) were studied. The different groups were tested for correlation with adverse findings. 2-sample T-tests assuming unequal variance were used.



On mpMRI the MSKCC unfavorable group had higher index lesion suspicion scores (p=0.044), while the ProCaRS model showed a higher maximum tumor diameter (MTD) in the high-risk group (p=0.047). At RP, a higher pathologic MTD (23.3 vs. 17.6 mm, p=0.005) was present in the MSKCC unfavorable group as well as the ProCaRS high vs. low group (26.6 vs. 19.3 mm, p=0.022).



Both models demonstrated a correlation with higher MTD for unfavorable IR patients. This is likely a driver of worse clinical outcomes.
Department of Radiation Oncology, University of California, Los Angeles, CA, U.S.A.
Timothy
T
Ellis-Caleo
Department of Radiation Oncology, University of California, Los Angeles, CA, U.S.A.
John V
JV
Hegde
Department of Radiation Oncology, University of Southern California, Los Angeles, CA, U.S.A.
Sukhjeet
S
Batth
Department of Radiation Oncology, University of California, Irvine, CA, U.S.A.
Shane
S
Mesko
Department of Urology, University of California, Los Angeles, CA, U.S.A.
Robert
R
Reiter
Department of Radiology, Weill Cornell Medicine, New York, NY, U.S.A.
Daniel
D
Margolis
Department of Radiation Oncology, Cedars Sinai Medical Center, Los Angeles, CA, U.S.A. mitchell.kamrava@cshs.org.
Mitchell
M
Kamrava
D000328:Adult; D000368:Aged; D001706:Biopsy; D004058:Diffusion; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008495:Medical Oncology / Q000379:methods* / Q000592:standards; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D009367:Neoplasm Staging; D018579:Patient Selection; D011379:Prognosis; D011467:Prostate / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000503:physiopathology*; D012189:Retrospective Studies; D018570:Risk Assessment; D016896:Treatment Outcome
D017430:Prostate-Specific Antigen
MSKCC; ProCars; maximal tumor diameter; mpMRI; prostatectomy